Skip to main content
. Author manuscript; available in PMC: 2010 May 12.
Published in final edited form as: Nature. 2009 Nov 1;462(7270):175–181. doi: 10.1038/nature08506

Figure 2. Testing new off-target activities.

Figure 2

(A-F) Radioligand competition binding assays: (A) Doralese at D4, (B) Sedalande and Dimetholizine at α1D, (C) Fabahistin at 5-HT5A, (D) Motilium at α1A, (E) Prozac at β1, and (F) Vadilex at the serotonin transporter. (G-H) Investigating 5-HT2A as the target of DMT-induced hallucination: (G) 5-HT2A-mediated Ca2+ response was measured after treating HEK 293 cells stably expressing the human 5-HT2A receptor with DMT or 5-HT. DMT's EC50 was found to be 118±29 nM (vs. 5-HT's 6.6±0.4 nM baseline, n = 3), with an Emax of 23±0.4% (n = 3), confirming that DMT is a potent partial agonist at 5-HT2A receptors. (H) DMT elicited head twitch behavior only in 5-HT2A wild-type mice, confirming that it is a hallucinogenic 5-HT2A agonist. **, p < .01.